A Phase 1b Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC).
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2012
At a glance
- Drugs Tivantinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 11 Jul 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
- 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.